Hormonal
DNA methylation levels in blood are significantly associated with specific blood serum metabolic traits (metabotypes), independent of underlying genetic variants, suggesting epigenetic regulation of human metabolism.
This research highlights that your metabolic health is not just written in your DNA sequence but is also regulated by epigenetic marks (DNA methylation) influenced by your lifestyle and environment. While this study doesn't prescribe a specific diet or exercise, it underscores the importance of lifestyle factors (like smoking cessation, noted as a driver for some associations) in maintaining healthy metabolic profiles through epigenetic regulation.
Taken together, our data suggest that DNA methylation plays an important role in regulating human metabolism.
Why this rating
Large population cohort (n=1814), epigenome-wide association study (EWAS), validation with EpiTYPER, but observational nature limits causal inference.
Source
Epigenetics meets metabolomics: an epigenome-wide association study with blood serum metabolic traits
Ann-Kristin Petersen et al. · Human Molecular Genetics · 2013
DOI 10.1093/hmg/ddt430
More from this paper
- Genetic variants can confound the association between DNA methylation and metabolic traits, creating apparent epigenetic links that are actually driven by genetics.Strong
- Smoking is a common external environmental factor driving specific DNA methylation patterns (VINYLPHENOL loci group) associated with 4-vinylphenol sulfate levels in blood.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →